A. Rapoport

D. Howard, D. Reece, A. Rapoport, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plasma cell dyscrasia in a 15-year-old boy: case report and review of the literature.

A. Rapoport, J. Rowe, 1990, The American journal of medicine.

Cardiac arrest after autologous marrow infusion.

A. Rapoport, J. Rowe, S. Ginsberg, 1991, Bone Marrow Transplantation.

Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma

A. Hamburger, A. Rapoport, A. Burger, 2008, Leukemia & lymphoma.

Acute glomerulonephritis in a hematopoietic blood stem cell donor

M. Weir, A. Rapoport, C. Drachenberg, 2021, Clinical nephrology. Case studies.

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A. Rapoport, Z. Singh, A. Badros, 2015 .

Life‐threatening autoimmune hemolytic anemia in a patient with the acquired immune deficiency syndrome

A. Rapoport, A. McMican, JACOB M. Roue, 1988, Transfusion.

Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature.

A. Rapoport, A. Badros, Karl M Kasamon, 2005, Haematologica.

Treatment and outcomes of post‐transplant lymphoproliferative disease: A single institution study

A. Rapoport, S. Bartlett, F. Buadi, 2007, American journal of hematology.

25 Dose escalation of consolidation radiation therapy (involved field) following autologous bone marrow transplant for recurrent Hodgkin's disease and lymphoma

R. Brasacchio, P. Rubin, L. Constine, 1996 .

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

M. Kersten, P. Riedell, L. Gordon, 2021, The New England journal of medicine.

Transfer of inﬂuenza vaccine–primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of inﬂuenza immunity: results of a randomized clinical trial

A. Jawad, K. Sullivan, B. Levine, 2010 .

Large Cell Lymphoma Presenting as a Flare of Colitis in a Patient with Common Variable Immune Deficiency

H. Yfantis, A. Rapoport, R. Cross, 2007, Digestive Diseases and Sciences.

Detection of CD4+ T‐cell antibodies in a patient with idiopathic CD4+ T lymphocytopenia and cryptococcal meningitis

A. Rapoport, D. Mann, R. Salit, 2007, British journal of haematology.

Granulomatous amebic encephalitis: an under‐recognized cause of infectious mortality after hematopoietic stem cell transplantation

I. Gojo, A. Rapoport, A. Uslu, 2011, Transplant infectious disease : an official journal of the Transplantation Society.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Adam Bagg, Marcela V Maus, Bent K Jakobsen, 2013, Blood.

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

J. E. Brewer, B. Levine, M. Kalos, 2015, Nature Medicine.

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

J. Vose, D. Miklos, A. Rapoport, 2019, Blood.

Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.

A. Rapoport, T. Ford, Asit K. Nandi, 2007, Biochemical and biophysical research communications.

Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: Two case reports and a review of literature

Y. Ning, I. Gojo, A. Rapoport, 2004, American journal of hematology.

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

Sonali M. Smith, Krishna Rao, A. Rapoport, 2020, Haematologica.

Phase 1 study of lenalidomide plus dose‐adjusted EPOCH‐R in patients with aggressive B‐cell lymphomas with deregulated MYC and BCL2

Sonali M. Smith, P. Venugopal, M. Bishop, 2019, Cancer.

Leukocyte-reduced transfusions of ABO-identical platelets and clinical outcome in autologous bone marrow transplantation for lymphoma.

A. Rapoport, J. Rowe, N. Blumberg, 1994, Bone marrow transplantation.

Successful Treatment of Toxoplasma Induced Hemophagocytic Lymphohistiocytosis (HLH) after Undergoing Allogenic Stem Cell Transplantation (HSCT)

A. Rapoport, S. Dahiya, J. Yared, 2019, Biology of Blood and Marrow Transplantation.

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

J. Vose, D. Miklos, A. Rapoport, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

K. Kong, D. Miklos, C. Mackall, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

J. Vose, D. Miklos, A. Rapoport, 2019, Blood.

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

W. Blackwelder, D. Porter, B. Levine, 2005, Nature Medicine.

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

Abraham Schneider, E. Sausville, A. Rapoport, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma

Naomi A. Sengamalay, L. Tallon, A. Rapoport, 2015, PloS one.

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

A. Rapoport, M. Fontaine, Z. Singh, 2019, American journal of hematology.

Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.

D. Atanackovic, A. Rapoport, S. Dahiya, 2023, Transplantation proceedings.

Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism

A. Rapoport, S. Yanovich, G. Akpek, 2014, Bone Marrow Transplantation.

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

P. Hari, D. Howard, D. Reece, 2018, Bone Marrow Transplantation.

Deep dissection of the antiviral immune profile of patients with COVID-19

T. Luetkens, D. Atanackovic, J. Baddley, 2021, Communications Biology.

Pattern of Use and Outcomes with Donor Lymphocyte Infusion (DLI) and Unmanipulated Stem Cell Boost (SCB) after Allogeneic Hematopoietic Stem Cell Transplant (HSCT): A Single-Center Experience

A. Rapoport, A. Emadi, S. Dahiya, 2019, Biology of Blood and Marrow Transplantation.

Successful treatment of IgG and complement‐mediated autoimmune hemolytic anemia with bortezomib and low‐dose cyclophosphamide

A. Rapoport, P. Danchaivijitr, J. Yared, 2011, American journal of hematology.

Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies

A. Rapoport, N. Ijaz, Nadia Ijaz, 2014 .

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

A. Jawad, K. Sullivan, B. Levine, 2011, Blood.

Plasma exchange and rituximab treatment for lenalidomide‐associated cold agglutinin disease

A. Rapoport, J. Hess, G. Akpek, 2012, Transfusion.

REL-positive double minute chromosomes in follicular lymphoma

Y. Ning, A. Rapoport, X. Zhao, 2006, Leukemia.

Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation.

A. Rapoport, S. Munigala, A. Godara, 2020, JCO oncology practice.

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

T. Luetkens, D. Atanackovic, A. Welm, 2022, Leukemia.

Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF.

A. Rapoport, Asit K. Nandi, 2006, Leukemia research.

PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21

Zhenqiu Liu, Hong-Bin Fang, R. Gartenhaus, 2010, Oncogene.

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

E. Sausville, A. Rapoport, D. Weikel, 2006 .

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

A. Rapoport, B. Meisenberg, A. Badros, 2005 .

Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy

E. Sausville, S. Stass, A. Rapoport, 2009, Clinical Cancer Research.

Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma

Seung Tae Lee, A. Rapoport, S. Dahiya, 2020, Leukemia & lymphoma.

Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature

A. Rapoport, R. Fenton, A. Badros, 2007, Cancer.

Posttransplant Classic Hodgkin Lymphoma: Richter Transformation or Posttransplant Lymphoproliferative Disorder?

A. Rapoport, Z. Singh, S. Hodges, 2019, AJSP: Reviews and Reports.

PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.

J. Toretsky, D. Ross, A. Rapoport, 2001, Blood cells, molecules & diseases.

Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.

J. Karp, M. Tidwell, A. Rapoport, 2004, Blood cells, molecules & diseases.

Encouraging preliminary results in 12 patients with high‐risk haematological malignancies by omitting graft‐versus‐host disease prophylaxis after allogeneic transplantation

G. Tricot, A. Rapoport, M. Cottler-Fox, 2000, British journal of haematology.

Check(point) or checkmate for acute myeloid leukemia?

A. Rapoport, S. Niyongere, 2021, Haematologica.

Check(point) or Checkmate for AML?

A. Rapoport, S. Niyongere, 2021, Haematologica.

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Bent K Jakobsen, J. E. Brewer, Gabriela Plesa, 2013, Science Translational Medicine.

T-Cell Therapeutics: Donor Lymphocyte Infusion, Cytotoxic T-Lymphocyte Infusion, and Other Non-CAR T-Cell Therapies

A. Rapoport, N. Majhail, Hamza Hashmi, 2021 .

T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challenges

A. Rapoport, J. Yared, 2018, Advances and Controversies in Hematopoietic Transplantation and Cell Therapy.

Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium.

D. Miklos, A. Rapoport, M. Lunning, 2019, Journal of Clinical Oncology.

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma

D. Atanackovic, Seung Tae Lee, A. Rapoport, 2021, British journal of haematology.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.

J. Vose, D. Miklos, A. Rapoport, 2020, Blood.

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

J. Vose, D. Miklos, P. Jain, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019.

A. Rapoport, S. Dahiya, Ali Bukhari, 2020, Critical reviews in oncology/hematology.

SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR‐T CONSORTIUM

J. Vose, D. Miklos, A. Rapoport, 2019, Hematological Oncology.

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Michael L. Wang, J. Vose, D. Miklos, 2021, Blood.

Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma

G. Tricot, J. Bolaños-Meade, I. Gojo, 2004, Bone Marrow Transplantation.

Lenalidomide‐induced eosinophilic pneumonia

A. Burke, A. Rapoport, A. Sachdeva, 2017, Respirology case reports.

Rejection - But in a Different Direction: Graft vs. Host Disease After Solid Organ Transplantation Mimicking an Infection.

A. Rapoport, S. Dahiya, Ali Bukhari, 2019, The American journal of medicine.

Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.

J. Karp, M. Tidwell, A. Rapoport, 2003, Leukemia research.

Involved field radiotherapy following auto-transplantation for lymphoma and Hodgkin's disease

R. Brasacchio, P. Rubin, L. Constine, 1994 .

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era

A. Rapoport, Brad Rybinski, A. Badros, 2022, Clinical Lymphoma Myeloma and Leukemia.

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, Blood.

Genomics trumps clinical criteria in BMT? Nyet!

A. Rapoport, N. Holtzman, 2017, Blood.

Comment on Yoshizato et al , page 2347 Genomics trumps clinical criteria in BMT ?

A. Rapoport, 2017 .

Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

G. Tricot, A. Rapoport, M. Cottler-Fox, 2001, Leukemia & lymphoma.

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

B. Levine, M. Kalos, C. June, 2013, Clinical Cancer Research.

Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

G. Tricot, M. Tan, I. Gojo, 2006, Bone Marrow Transplantation.

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

A. Lesokhin, A. Rapoport, E. Hyjek, 2016 .

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.

J. Vose, F. Gao, D. Miklos, 2022, Clinical Lymphoma, Myeloma & Leukemia.

C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade

A. Rapoport, C. Shanholtz, S. Dahiya, 2020, Leukemia & lymphoma.

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

N. Geller, N. Munshi, M. Pasquini, 2021, Blood.

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Wei-Ting Hwang, Bruce L Levine, B. Levine, 2019, Blood advances.

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

K. Kong, D. Miklos, C. Mackall, 2019, Blood.

Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.

K. Kong, D. Miklos, I. Kirsch, 2019, Journal of Clinical Oncology.

Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

T. Luetkens, D. Atanackovic, A. Spivak, 2020, Blood Advances.

Humoral immune responses against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine

T. Luetkens, J. Baddley, A. Rapoport, 2022, medRxiv.

Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy

G. Tricot, I. Gojo, A. Rapoport, 2001, Bone Marrow Transplantation.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

E. Sausville, A. Rapoport, M. Baer, 2015, Cancer.

Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant.

J. Dipersio, A. Rapoport, J. Rowe, 1991, Bone marrow transplantation.

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

A. Rapoport, R. Amado, E. Stadtmauer, 2017 .

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

B. Levine, C. June, J. Melenhorst, 2018, Blood.

Myeloma escape from immunity: an "inside" job.

A. Rapoport, 2015, Blood.

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

A. Lesokhin, A. Rapoport, A. Badros, 2019, Blood advances.

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)

T. Luetkens, D. Atanackovic, K. Dunleavy, 2023, Human vaccines & immunotherapeutics.

Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma

A. Rapoport, X. Zhao, S. Chumsri, 2007, Leukemia & lymphoma.

Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

S. Grupp, B. Jakobsen, W. Tap, 2015 .

Survival analysis with functional covariates for partial follow-up studies

Hong-Bin Fang, Ming Tan, M. Tan, 2016, Statistical methods in medical research.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, New England Journal of Medicine.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

M. Kersten, P. Riedell, D. Miklos, 2023, The New England journal of medicine.

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

A. Tomkinson, I. Gojo, A. Rapoport, 2013, Oncogene.

Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant

T. Luetkens, D. Atanackovic, J. Baddley, 2021, Vaccines.

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

E. Sausville, A. Rapoport, Z. Singh, 2016, Bone Marrow Transplantation.

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Sonali M. Smith, Krishna Rao, A. Rapoport, 2016 .

Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants.

L. Constine, J. Liesveld, C. Abboud, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells

T. Luetkens, D. Atanackovic, A. Rapoport, 2023, Haematologica.

Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.

D. Atanackovic, A. Rapoport, Wengen Chen, 2021, Clinical lymphoma, myeloma & leukemia.

Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years.

J. Dipersio, M. A. Tanner, L. Constine, 1995, Bone marrow transplantation.

Donating used CARs.

A. Rapoport, 2013, Blood.

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

M. Tan, B. Levine, C. June, 2011, Blood.

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

B. Levine, M. Kalos, C. June, 2013, Clinical Cancer Research.

Tocilizumab Is Effective Therapy for Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

A. Rapoport, S. Yanovich, A. Badros, 2016 .